The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI

摘要: Background The MRC UKALLXI trial tested the efficacy of different central nervous system (CNS) directed therapies in childhood acute lymphoblastic leukaemia (ALL). To evaluate morbidity 555/1826 randomised children underwent prospective psychological evaluations. Full Scale, verbal and performance IQs were measured at 5 months, 3 years years. Scores compared in; (1) all patients (n = 555) versus related controls 311), (2) low-risk (presenting white cell count (WCC) < 50 × 109/l) to intrathecal methotrexate 197) high-dose intravenous (HDM) 202), (3) high-risk (WCC ≥ 109/l, age 2 years) HDM 79) cranial irradiation 77).